Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Since 2006, BioWin, the health cluster of the Belgian region of Wallonia, has powered a renaissance of technological and scientific excellence in cell therapy and regenerative medicine.
Benitec Biopharma’s DNA-directed RNA interference platform can generate single-application therapies to silence defective genes in a wide range of diseases whilst overcoming many of the limitations of short interfering RNA.
Vaccinex’s proprietary full-length human antibody discovery engine, ActivMAb, integrates selection and manufacturing in the same mammalian host to streamline development.
The French Institute of Health and Medical Research (Inserm) has developed a unique model for technology transfer through Inserm Transfert, its subsidiary in charge of de-risking innovative preclinical projects and bridging discovery and clinical research.
Histide’s Cell Recoding Molecules provide a diverse source of nonmutagenic extracellular therapeutic agents for tissue regeneration and disease healing.
Probiodrug’s novel approach targets a modified form of β-amyloid, which has a key role in the creation of toxic Aβ oligomers. The company’s lead product is a first-in-class oral small-molecule glutaminyl cyclase inhibitor.